PARP Inhibitor-Based Triplet Promising in Endometrial Cancer - Medpage Today
4/11/2022 12:00:00 AM3 yearsago
by Mike Bassett
by Mike Bassett
Olaparib/cyclophosphamide/metformin combo appears effective in older, heavily pretreated patients
NEW ORLEANS -- A triplet combination of the PARP inhibitor olaparib (Lynparza), metronomic cyclophosphamide, and metformin was feasible and showed encouraging efficacy in elderly, heavily pretreated … [+4817 chars]
full article...